PHNT NilotinibNF2

• Research type

  Research Study

• Full title

  A Clinical Trial Of The Intra-Tumoural Concentration And Activity Of Nilotinib In Intra-Cutaneous Schwannomas

• IRAS ID

  60345

• Contact name

  Clemens Hanemann

• Sponsor organisation

  Plymouth Hospitals Research and Development

• Eudract number

  2010-023508-28

• ISRCTN Number

  n/a

• Clinicaltrials.gov Identifier

  n/a

• Research summary

  This is a small study in 15 patients with a hereditary tumour syndrome called Neurofibromatosis 2 (NF2) in Plymouth and Manchester. Patients have a cutaneous tumour biopsy and are treated for 14 days with a drug called Nilotinib and then get a second biopsy. The aim is to ensure that the drug gets into the tumour and inhibits the molecular pathways it should. Patients are followed up after the last biopsy for another 14 days.

• REC name

  South Central - Berkshire Research Ethics Committee

• REC reference

  11/SC/0035

• Date of REC Opinion

  14 Apr 2011

• REC opinion

  Further Information Favourable Opinion